Evogene (TSE:EVGN – Get Free Report) had its target price reduced by stock analysts at Desjardins from C$4.00 to C$3.00 in a research report issued on Tuesday,BayStreet.CA reports. The firm presently has a “buy” rating on the stock.
Separately, Ventum Financial cut their target price on Evogene from C$4.00 to C$3.00 in a research report on Friday, November 22nd.
Get Our Latest Analysis on EVGN
Evogene Price Performance
About Evogene
Evogene is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and guide the development of life-science products based on microbes, small molecules and genetic elements.
See Also
- Five stocks we like better than Evogene
- Insider Buying Explained: What Investors Need to Know
- GitLab: Get In While It’s Down—Big Rebound Ahead
- What Does a Stock Split Mean?
- Tesla Stock: Finding a Bottom May Take Time
- Learn Technical Analysis Skills to Master the Stock Market
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
